Novartis targets oncologists with blog

Share this article:
Novartis is experimenting with blogging for physicians with melanomaperspectives.com.
Executed by Compass Healthcare Communications, it went live in August with a panel of five knowledge and opinion leader contributors.

Though the site is unbranded, Novartis hopes to educate referring and community oncologists about the benefits of interleukin-2 therapies like the company's Proleukin, for metastatic melanoma and metastatic kidney cancer. A late-stage treatment, Proleukin suffers from a lack of awareness regarding the timing and usage of immunotherapy versus chemotherapy.

As the site does not have comments, Novartis doesn't have to worry about the thorny issue of adverse events reporting. All content is reviewed by the company for medical, regulatory and legal correctness before posting. It will be supported by search engine optimization, details and banner ads.  

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"